Measles Outbreaks and Implications for Patients Receiving Stem Cell or Cellular Therapies in Canada: Cell Therapy Transplant Canada (CTTC) Infectious Diseases Working Committee.

Simon F Dufresne, Mohammadreza R Shahmirzadi, Uday Deotare, Dima Kabbani, Shahid Husain, Coleman Rotstein, Seyed M Hosseini-Moghaddam

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simon F DufresneDivision of Infectious Diseases and Medical Microbiology, Department of Medicine, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC H1T 2M4, Canada.ORCID 0000-0002-2486-5813

Mohammadreza R ShahmirzadiDivision of Infectious Diseases, Department of Medicine, London Health Sciences Centre, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0002-2410-6788

Uday DeotareDivision of Haematology, Department of Medicine, London Health Sciences Centre, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0001-9391-4204

Dima KabbaniDivision of Infectious Diseases, Department of Medicine, University of Aberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0003-3785-1098

Shahid HusainAjmera Transplant Centre, Division of Infectious Diseases, Department of Medicine, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada.

Coleman RotsteinAjmera Transplant Centre, Division of Infectious Diseases, Department of Medicine, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0003-1413-0968

Seyed M Hosseini-MoghaddamAjmera Transplant Centre, Division of Infectious Diseases, Department of Medicine, University Health Network, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0001-7979-2458

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measles exposures have historically been rare since the introduction of routine vaccination programs, resulting in a lack of attention from cancer patients, hematopoietic stem cell transplant (HCT) recipients, patients receiving cellular therapy (CT) and their healthcare providers. It is essential to acknowledge the importance of vigilance in these situations. Measles herd immunity has declined significantly in North America due to rising vaccine hesitancy, resulting in outbreaks. Measles can result in severe outcomes, and its reemergence has raised alarm among patients and healthcare professionals caring for HCT/CT recipients. Patients with severe immunocompromising conditions cannot receive live-attenuated vaccines, such as the measles vaccine. The lack of data on measles prevention in this vulnerable group presents significant clinical challenges. In response, Cell Therapy Transplant Canada (CTTC) Infectious Diseases Working Committee has developed a set of frequently asked questions to provide expert guidance to HCT and CT recipients, acknowledging the limited evidence base.

Indexed as

Cell- and Tissue-Based TherapyDisease OutbreaksHematopoietic Stem Cell TransplantationMeaslesStem Cell TransplantationCanadaHumanscell therapylive-vaccinemeaslesMMR vaccinestem cell transplantation

Identifiers

PMID41002595

DOI10.3390/curroncol32090525

PMCPMC12468672

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.